Anemia
Advertisement
Oral and intravenous iron supplementation effectively treated restless legs syndrome in patients with iron deficiency anemia.
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
The MAA for RP-L102, an investigational gene therapy for Fanconi anemia, has been approved by the EMA.
Dr. Sharathkumar shared data from her 2024 ASPHO presentation on romiplostim in children with severe aplastic anemia and MDS.
The European Commission approved an expanded indication for luspatercept as first-line therapy for anemia in lower-risk MDS.
The US FDA has approved vadadustat to treat anemia due to CKD in adults who have been on dialysis for at least three months.
The US FDA ODAC voted that the benefits of imetelstat for managing anemia in lower-risk MDS outweigh the risks.
Iptacopan monotherapy improved hematologic and clinical outcomes of persistent anemia in patients with PNH.
The researchers evaluated surveys sent between 2015 and 2023 to patients with severe aplastic anemia who underwent HSCT.
Requiring dialysis before HSCT is associated with “very poor outcomes,” according to the study.
Fludarabine, cyclophosphamide, and ATG had superior outcomes versus historical outcomes of non-ATG conditioning.
This would be the fourth authorized indication for luspatercept in the European Union.
HSCT with a matched unrelated or haploidentical donor was a promising alternative in patients with severe aplastic anemia.
Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia.
Low hemoglobin and anemia were found to be modifiable risk factors associated with low cognitive function in older patients.
C1-inhibitor administration during transfusions did not significantly suppress hemolysis in autoimmune hemolytic anemia.
Iron deficiency anemia was associated with subsequent diagnosis of gastrointestinal cancers, particularly colorectal cancer.
Letermovir reduced the rate of CMV infection within the first 100 days of transplant.
Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors may be a safer and more effective alternative to ESAs.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.